Review of synthetic cannabinoids out-of-date as soon as it’s published
January 19, 2016, 11:38 pm
A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Tait RJ et al. Clin Toxicol 2016 Jan;54:1-13.
This paper review clinical literature related to use of synthetic cannabinoids (SCs) through the end of 2015. Although it seems comprehensive, and cites 108 references, it is of course already at least 18 months out-of-date. The number of cases involving exposure to SC surged during 2015. For example, although the authors of this paper identified 22 deaths associated with SCs, according to CDC data in the first 6 months of 2015 alone 15 people died from exposure to the drugs.
Since SCs are a moving target — with new compounds appearing almost daily — year-and-a-half old data is just not that compelling. However, some of the authors main points still hold up:
- most patients present with relatively mild manifestations including tachycardia, agitation, and nausea
- more serious adverse effects include, myocardial infarction, arrhythmias, acute kidney injury, seizure, and acute psychosis
- supportive care usually suffices